Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elecoglipron - Eccogene

Next Previous
Drug Profile

Elecoglipron - Eccogene

Alternative Names: AZD-5004; ECC-5004

Latest Information Update: 10 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eccogene
  • Developer AstraZeneca; Eccogene
  • Class Antihyperglycaemics; Benzimidazoles; Cyclic ethers; Cyclopropanes; Fluorinated hydrocarbons; Fluorobenzenes; Hepatoprotectants; Indazoles; Indolizines; Ketones; Obesity therapies; Oxadiazoles; Piperidines; Pyrans; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus
  • Phase I Liver disorders
  • No development reported Non-alcoholic steatohepatitis

Most Recent Events

  • 13 Mar 2026 AstraZeneca initiates a phase I pharmacokinetic trial (In volunteers) in Japan (PO) (NCT07444424)
  • 06 Mar 2026 AstraZeneca plans a phase I PK trial for Healthy volunteers in USA (PO) in March 2026 (NCT07455825)
  • 05 Mar 2026 AstraZeneca initiates enrolment in a phase I PK trial for Healthy volunteers in USA (PO) (NCT07455825)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top